Using pharmacoeconomics to value pharmacotherapy

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 2, 2008, Pages 197-200

  Hay, J W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; IMATINIB; IMIGLUCERASE; TRASTUZUMAB;

COLON CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; SHORT SURVEY; SURVIVAL TIME; TREATMENT PLANNING;

EID: 49149109126     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.124     Document Type: Short Survey

References (10)

1. Szabo, L. Prices soar for cancer drugs. USA TODAY, 11 July 2006.
2. Neumann, P. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers (Oxford Univ. Press, New York, 2004).
3. Hay, J. Application of cost effectiveness and cost benefit analysis to pharmaceuticals. In The Grand Bargain: Ethics and the Pharmaceutical Industry in the 21st Century. (eds. Santoro, M. & Gorrie, T.) 225-248 (Cambridge Univ. Press, New York, 2005).
4. Gold, M., Siegel, J., Russell, L. & Weinstein, M. Cost-Effectiveness in Health and Medicine (Oxford Univ. Press, New York, 1996).
5. Hay, J. Evaluation and review of pharmacoeconomic models. Expert Opin. Pharmacother. 5, 1867-1880 (2004).
6. International Society for Pharmacoeconomics and Outcomes Research. Comparative Table [PE guidelines] 〈http://www.ispor.org/ PEguidelines/COMP1.asp〉. Accessed April 2008.
7. Fry, R.N., Avey, S.G. & Sullivan, S.D. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard. Value Health 6, 505-521 (2003).
8. Center for the Evaluation of Value & Risk in Health. Cost Effectiveness Analysis Registry (CEA) 〈http://www.cearegistry. org〉. Accessed April 2008.
9. Archimedes. Archimedes: Moving Medicine Through Mathematics 〈http://www.archimedesmodel.com〉. Accessed April 2008.
10. Wilensky, G.R. Developing a center for comparative effectiveness information. Health Affairs 25, w572-w585 (2006).